Experienced in Hyperlipoproteinemia Type 5

Dr. Mohammed A. Allaw

Internal Medicine
Deaconess Clinic Inc
4015 Gateway Blvd, 
Newburgh, IN 
 (549.5 mi)
Accepting New Patients
Experienced in Hyperlipoproteinemia Type 5
Deaconess Clinic Inc
4015 Gateway Blvd, 
Newburgh, IN 
 (549.5 mi)
OverviewInsuranceLocationsClinical Research

Overview

Mohammed Allaw is an Internal Medicine provider in Newburgh, Indiana. Dr. Allaw and is rated as an Experienced provider by MediFind in the treatment of Hyperlipoproteinemia Type 5. His top areas of expertise are High Cholesterol, Infant Hyperglycemia, Lung Cancer, Cirrhosis, and Endoscopy. Dr. Allaw is currently accepting new patients.

His clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in IN
Hospital Affiliations
Owensboro Health Regional Hospital
Ferrell Hospital Community Foundations
Women's Hospital The
Deaconess Hospital Inc
Deaconess Henderson Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Anthem
  •  CareSource
  •  Humana

Locations

DEACONESS CLINIC INC
4015 Gateway Blvd, Newburgh, IN 47630
Other Locations
DEACONESS CLINIC INC
1204 Williams St, Oakland City, IN 47660
DEACONESS HOSPITAL INC
4099 Gateway Blvd, Newburgh, IN 47630
DEACONESS CLINIC INC
421 Chestnut St, Evansville, IN 47713
DEACONESS HOSPITAL INC
600 Mary St, Evansville, IN 47710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Biological, Drug
Study Drug: Mepolizumab
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: October 08, 2024
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile